UCB's Neupro hits US market again
This article was originally published in Scrip
Executive Summary
UCB has again launched its once daily rotigotine patch Neupro in the US for patients with the signs and symptoms of idiopathic Parkinson's disease and moderate to severe primary Restless Legs Syndrome. First launched in the US in 2007, the firm voluntarily recalled the drug there the following year.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.